Brandon Young has 20 years of experience utilizing technology to improve testing and detection of genetic variation in human diseases. He was one of the early laboratory pioneers in microarray and gene sequencing projects in startup companies and large academic institutions. He has extensive experience in research, set-up, operations, configuration and P&L of running genomics labs. He has provided data and analysis for multiple national and international clinical trials.
Brandon has helped design, build and run labs for a number of prestigious centers throughout the US, including Scripps Florida, Human Longevity Institute (HLI), and Avera McKennan. His current work with the Darwin Foundation is providing next generation sequencing services to support groundbreaking clinical studies for the WIN consortium, focusing on personalized precision oncology testing and treatment protocols. This early stage work is generating over 50% improvements in clinical outcomes for participating cancer patients.
Deepankar Roy is a trained research scientist and has worked on several cell line engineering platform technologies at Larix Bioscience and Genentech. Prior to these roles, he was a postdoctoral fellow at Genentech’s Research Oncology division where he studied cancer signaling pathways. Deepankar completed his doctoral studies in Biochemistry and Molecular Biology at University of Southern California where he undertook a reductionist approach in studying nucleic acid behavior in mammalian immune systems.
He has worked with early stage life science companies as Director of Business and Scientific Operations at Venomyx Inc., an antivenom therapeutics startup and as the Director of Business/Product Development at Colby Pharmaceutical Company and its subsidiary CancerVacs Inc, companies involved in development of immunotherapeutics for allergy, cancer and other diseases.
Jay Goth is the Managing Partner of Forentis Fund, a biotech venture capital firm focused on precision medicine. He is a veteran entrepreneur, with experience in the hospitality, energy, finance and technology verticals. As a founding executive of Commonwealth Energy, Jay helped the company go from start-up to almost $500 million in revenues in five years, becoming the largest unregulated supplier of electricity and natural gas in the country when the company went public on the AMEX.
He serves as Executive Director of InSoCal CONNECT, a nonprofit that has structured mentorship and training programs for entrepreneurs, was a Senior Consultant with TriTech SBDC, one of seven technology designated Small Business Development Centers operating under the SBA, and served as an Entrepreneur in Residence at the University of California Riverside. Jay also serves on the board of directors for Credence Code Technologies, Inc., a company focused on blockchain development and implementation. He also serves on the board of Burble, a company that delivers the power of story through minimally defined immersive environments. Jay is on the board of directors for InSoCal CONNECT and Reach Out, nonprofits dedicated to improving lives in the Inland Empire.
John Powers spent 22 years in the wireless industry driving acceptance and adoption of new technologies. His background in wireless convergence, and cloud computing is complimentary to the goals of the medical industry, especially in integrating the large amount of genetic/genomic data into everyday medicine.
As CEO of IntraOp Medical, John worked with multiple discipline teams including physicists, surgeons, radiation and medical oncologists in the top cancer centers around the world. Working with the Centers for Medicare & Medicaid Services (CMS) John was able to secure a new reimbursement code and reimbursement for Intra-Operative Radiation Therapy (IORT). He more than tripled IntraOp’s installed customer base, making the company profitable in 2012, followed by a take private restructuring and change of ownership.
We have assembled a dynamic and dedicated group of advisory board members to provide guidance to our incubator companies. Their crucial insights and experience will be invaluable to our startups. Most early stage companies would never have access to this type of knowledge base – one of the many benefits our clients enjoy.
Dr. Jay Harness is a surgeon specializing in complete breast health, breast cancer surgery, oncoplastic reconstruction, genetic screening, risk assessment and counseling, management of breast health issues and Breast Cancer Treatment in Orange County, California and is a global leader in the fight against breast cancer.
He most recently served as President of Breast Surgery International, and has served in leadership roles within a number of national and international professional associations including, most notably, as President of the American Society of Breast Surgeons from 2007 to 2008. Dr. Harness is the Chairman of Murrieta Genomics’ Advisory Board.
Ronnie Andrews is the Founder and Principal of The Bethesda Group, a company focused on helping organizations in the molecular diagnostics and genomics industries. Prior to founding The Bethesda Group, he served as President of the Genetic Sciences Division at Thermo Fisher Scientific following a merger with Life Technologies, where he served as President of the Medical Sciences Venture. During the merger, he oversaw the integration of Ion Torrent with the traditional genetic platform and content initiatives within Life Technologies to form a $2 billion division.
Previously, Ronnie served as Chief Executive Officer and Segment Leader of GE Molecular Diagnostics at Clarient Inc. from 2004 until 2012. During this time, he oversaw the transition into GE Healthcare and established a strategic plan to integrate In Vivo and In Vitro and expand GEís presence in oncology. While at Clarient, he transformed ChromaVision Medical Systems from a device manufacturer to a comprehensive cancer diagnostics company.
Ronnie currently serves on the Board of Directors of Insight Genetics, Orion Healthcare, and Oxford Immunotec.
Steve Austin, MBA, CPA is Managing Partner for Swenson Advisors, LLP, a regional CPA firm (registered with the PCAOB), specializing in audit, tax, SEC, Sarbanes-Oxley, lease accounting and consulting engagements with a focus on technology, manufacturing, service, software, real estate, and non-profit organizations.
Steve manages audit, SEC, Sarbanes-Oxley, and business consulting engagements with a focus on technology, manufacturing, service, real estate, social media, and non-profit organizations. He is the author of the book ìRise of the New Ethics Class.î Steve speaks worldwide on governance, Sarbanes-Oxley, and IFRS matters and writes articles published by the AICPA.
Prior to joining Swenson Advisors, LLP, Mr. Austin accumulated over 22 years of experience as an Audit Partner with Price Waterhouse LLP, where he worked from 1976 to 1996, and with McGladrey & Pullen, LLP, where he worked from 1996 to 1998, serving both public and private companies. While at Price Waterhouse, Mr. Austin worked in the PW National Office in New York, where he addressed complex accounting and reporting issues for publicly-traded companies and worked with various members of the FASB and EITF staffs.
Shep began his career in 1984 at the Hospital Corporation of America as a research technician, produced drugs at Kendall-McGaw Laboratories, Inc. in Irvine, and became responsible for GMP compliance.
He has since become a regulatory affairs consultant, joining the Drug Information Association, speaking at the Parenteral Drug Association and joining the managements of ACTUS Biotech, Pharmakos, Inc., the Board of Directors of the Life Sciences Industry Council (LINC) of Orange County/Los Angeles County, and the Program Committee of the Orange County Regulatory Affairs Discussion Group.
He has been responsible for regulatory strategies leading to FDA and foreign approvals for several biotech companies. He has achieved market entry for numerous innovative medical technologies and applications within the European Union, Canada, Brazil and across Asia. Previously, Shep formed Synergy Biomedical, LLC, served as its President in collaboration with Washington D.C.-based Synergy, Inc. to provide biomedical regulatory expertise to the device and pharmaceutical industry of Southern California.
He speaks regularly at regulatory conferences, has co-authored a book on regulatory strategy as well as contributed to Genetic Engineering & Biotech News (GEN), and provides independent consulting for clients of Intertek.
He is an active member of the American Society for Quality – Biomedical Section (ASQ), the Regulatory Affairs Professional Society (RAPS), and The Organization for Professional Regulatory Affairs (TOPRA).
Mr. Bentley also served eight years of active duty as an officer in the United States Marine Corp, including as a part of the Marine Expeditionary Force (Forward), deployed to Ash Shuaybah, Kuwait, to prosecute the invasion into Baghdad, Iraq, and then redeployed to Office of Force Transformation, in the Pentagon. He was awarded the Meritorious Service Medal by the President of the United States, twice, and retired from military service in 2005.
Bill has previously served as Head of Genomic Sequencing at Human Longevity, Inc. Dr. Biggs came to Human Longevity from the Clinical Research Sequencing Platform (CRSP) at the Broad Institute of MIT and Harvard where he served as Director of Clinical Sequencing. In his role at CRSP he and his team supported pivotal clinical diagnostic, research and trials efforts to identify applications for deep sequencing in the process of medical decision-making. He was also responsible for assisting in the assembly of an evidence base required for broad-based reimbursement and utilization of deep sequencing in patient management.
Prior to joining the Broad Institute Dr. Biggs served as Director of Genetics and Genomics at Aviir Diagnostic Laboratories. Prior joining Aviir, Dr. Biggs as Director of Technical Operations, was a member of the founding team at Affymetrix Clinical Service Laboratories. He has extensive experience in elucidating the roles of genetics, signal transduction and transcriptional regulation during the initiation of progression of disease gained during studies conducted at The Salk Institute, The Ludwig Institute for Cancer Research, and Ambit Biosciences.
Dr. Biggs obtained his Ph.D. in Biological Chemistry from UCLA in 1994. Over the past decade, Bill has built a number of testing laboratories, all with the goal of driving the acceptance and utilization of cutting-edge molecular biology in routine medical practice.
Scott is an angel investor, startup mentor and the Director of EPIC SBDC at the University of California Riverside.
Scott has been a Founder or Founding Executive of a number of startups including the VC funded mobile games studio Muti Labs, the Temecula based sports tech company NZN Labs/LIT Pro and he sold his first company, Industrial Strength Network (an early interactive agency), to frog design as an acquihire in 1998.
Scott was part of the global leadership team at Disney that worked for the three years to build The Avengers franchise into a global powerhouse with his focus being the interactive games space. He led the successful launch of Avengers Alliance on Facebook and Avengers Initiative on mobile and with 40 million plus people having played the games, they have been a hit with the fans and critics alike.
Scott pioneered a big idea and an industry first, premiering The Hulk TV spot promoting the film in the Facebook game before it aired on national television. He championed and helped build a community called Marvel XP – a free live service that tracks gamer progression, rewards achievement and provides connected storytelling across Marvel mobile and social games. Scott has a Humanities Honors degree from The University of Texas at Austin where he graduated Magna Cum Laude and Phi Beta Kappa.
Joe serves as a corporate development & investment banking advisor to entrepreneurs, Boards, C-Suites, & UHNW. He possesses significant in-country international operating and cross border transaction experience throughout APAC, EMEA and the Americas. He is currently advising clients on institutional grade, SEC compliant TGEs with a global team of over 100 blockchain / crypto / DLT / decentralization advisors, consultants, financiers, and legal experts in eighteen time zones.
Joe is relationship driven with start-up through IPO C-Suite operator experience and early stage tech venture capital Managing Director experience. This vast understanding of both buy and sell side transaction perspectives allows him to position, design, and execute at maximize client value. An expert in strategic planning/analysis, transaction execution/design, and financial modeling/valuation, he has generated and executed dozens of M&A, strategic partnership, and capital related transactions as an external independent advisor.
Specialties: Corporate Development, Growth Strategy, Alliances, Partnerships, M&A, Cross Border, SPV, Capital, Crypto, Divestment, Exits, International, Partnerships, Business Development, Technology, Biotechnology, Stem Cells, Genomics, Transgenics, Proteomics, MedTech, Healthcare, Blockchain, DLT, Digital, IT, Software, EdTech, Predictive Analytics, Big Data, Real Estate Development, Investments, Investment Banking, Capital, Venture Capital, Private Equity, Activist, UHNW, Sovereign, Seed, Series A, Series B, IPO, ICO, TGE, Tokens, Philanthropy, Social Impact, Non-Profit, Financial Models, Projections, DCF, Valuation, Business Plan Development & Evaluation, White Papers, Transaction Due-Diligence.
Marek has 25 years of Wall Street experience as a portfolio manager and equity analyst with leading financial institutions. Most recently, he worked at BMO Global Asset Management, one of the worldís largest asset managers, as the global head of healthcare research. His other experience includes Vestor Capital, Nesbitt Burns Securities and Perritt Capital Management.
Throughout his investment career, Ciszewski acquired extensive experience in fundamental security analysis and selection, portfolio management and investment strategy. This was underpinned by his innate curiosity and relentless focus on understanding the various business models in the life sciences industry.
Ciszewski’s understanding of investor relations and capital markets is further complemented by his biopharma industry experience. He has held various senior corporate roles, including vice president of corporate development at Verastem, an oncology-focused biopharmaceutical firm, and head of investor relations and corporate communications at Epirus Biopharmaceuticals, a biosimilars pioneer.
His passion for his craft and unique combination of skills, experience and education make him invaluable to companies both preparing to go public and existing public companies that require deep industry knowledge along with a comprehensive suite of IR services.
Leila is an accomplished healthcare sales executive, business development leader and influencer. Her executive leadership experience in sales and marketing ranges from small start-up organizations to Fortune 500 companies within the pharmaceutical, biotechnology, and personalized medicine landscape.
Leila has spent her career implementing new sales and marketing initiatives to consistently drive revenue growth. These strategic initiatives have spanned multi-channel (regional, national, and global) to effectively position products and therapeutics to quickly secure solid market share.
Leila is a nationally recognized influencer among oncologists and key opinion leaders (KOLs), has led cross-functional teams, aggregated multiple advisory boards and commercialized sales teams to exceed revenue expectations. She is the recipient of multiple local and national achievement awards.
Leila has extensive business development experience in biotechnology, molecular diagnostics, pharmaceuticals, genomics, next-generation sequencing, biomarkers, innovation, and personalized medicine. Her deep knowledge ranges across therapeutic, diagnostic and the liquid biopsy landscape; inclusive of oncology, cardiology, neurology, gastroenterology, psychiatry, nephrology, infectious disease, pulmonology, endocrinology, rheumatology, HIV, womenís health and wellness.
Leila received both her Bachelorís of Arts (B.A.) and Executive MBA (EMBA) from Pepperdine University, CA, graduating with Beta Gamma Sigma Honors. She is an active member of the Healthcare Businesswomenís Association (HBA), Women in Bio, a Council Member of the American Cancer Society, member Kappa Kappa Gamma Sorority, a chosen Ambassador of Pepperdine University, and an active member of her Alumni association.
With an indefatigable, pioneering and entrepreneurial spirit, DeeDee has taken Bench International from its founding in 1974 to its eminence today as one of the most successful companies ìshatteringî diversity ceilings bringing women, people of color, as well as those who “think” and “do” differently to leadership roles in life science companies. In 2009 DeeDee was the first executive recruiter to be named “1 of the Top 100 Most Inspiring Leaders” by PharmaVOICE Magazine, and is a Hall of Fame Inductee of the National Association of Women Business Owners (NAWBO).
Being cause-motivated and giving back is critical to DeeDee, and she has devoted decades to serving as a member of multiple non-profit boards. She is a founding board member of Learning Forum International (LFI), Making Great Kids Greater through student and educator programs that contribute to the mastery of learning and life skills by todayís youth. Recently, DeeDee was appointed to the Advisory Board of BIOCOM, in an effort to bridge BIOCOMíS impact beyond San Diego County and to create a strong state-wide alliance. DeeDee is also a board member of The Maple Counseling Center (TMCC), a non-profit organization committed to providing low cost comprehensive mental health services for individuals of all ages, couples, and families, as well as providing training for interns and counselors who are working towards licensure in the mental health field.
DeeDeeís prior non-profit board commitments have included founding the Forum for Global Pharmaceutical Diversity and Inclusion (FRXDI), serving as a member of the board for Californiaís Chapter of the Israel International Cancer Research Fund (ICRF), Family Promise, and founding board member of Healthcare Business Womanís Associationís (HBAís) Europe Chapter.
DeeDee holds a double Masters of Science degree, Auditory Pathology and Speech Pathology. Prior to founding Bench, DeeDee served as a Research Fellow in a joint research program sponsored by National Institute of Health (NIH) and Siemens Corporation, the University of California, San Diego, State Diego State University and the San Diego Speech and Hearing Center.
Dr. Leyland-Jones received biochemistry, medical and doctoral degrees from the University of London and completed his residency at Hammersmith, Brompton, St. Bartholomewís and London hospitals. He then conducted fellowships at Cornell University and Memorial Sloan-Kettering Cancer Center. He became part of Sloan-Ketteringís medical staff, researching new anti-cancer compounds.
From 1983-1990, Dr. Leyland-Jones served at the National Cancer Institute as head of Developmental Chemotherapy and he oversaw the development of approximately 70 anti-cancer compounds. From 1990-2000, he was the director of the McGill University Comprehensive Cancer Centre and the founding chair of Oncology. Dr. Leyland-Jones also served as a professor of medicine at McGill University. From 2007-2012, he was the Director of the Winship Cancer Institute at Emory University, as well as a Professor of Medicine and Associate Vice-President of Health Sciences.
Dr. Leyland-Jones has also worked in the private sector. He became Founding Chairman and Chief Executive Officer of Xanthus (a biotech company focused on individualized cancer therapies in 2001), and he has been the Director of Genta, Inc. since April 2012. Dr. Leyland-Jones is also a member of the Scientific and Clinical Advisory Boards at Welichem Biotech Inc. and Antigen Express Inc.
Currently, Dr. Leyland-Jones is the Vice President of Molecular and Experimental Research at the Avera Cancer Institute and the Director of the Darwin Foundation. Dr. Leyland-Jones has held leadership positions in many large medical organizations, including the Eastern Cooperative Oncology Group, the Tissue Bank Consortium in Asia (that was founded and operated by NFCR), the Cancer and Leukemia Group B, the International Breast Cancer Study Group, the National Cancer Institute of Canada and Breast International Group. He is also the Director of the Darwin Foundation (formerly the Consortium for Clinical Diagnostics) that provides a centralized infrastructure where disease genes and genetic signatures can be identified and validated.
He has received many awards and honors throughout his career, including the Vivian Saykaly Visiting Professor Award by the Cedars Cancer Institute in Montreal and being named an Eminent Scholar by the Georgia Research Alliance and a Distinguished Cancer Scholar by the Georgia Cancer Coalition.
Throughout his career, Dr. Leyland-Jones has written more than 180 peer-reviewed articles and book contributions, and he holds 34 patents.
Kristine leads Bench International’s corporate strategy, utilizing her skills in evaluating macro trends and competitive strategies in the life sciences industry. She plays a key role in the execution of Benchís confidential and proprietary Board Diagnostic Assessments, identifying critical themes and recommendations for both public and private company Boards.
Prior to joining Bench, Kristine served as a Consultant at Deallus Strategic Intelligence Consulting, directing global teams in projects with Fortune 500- and Forbes Global 2000- ranked pharmaceutical and biotech companies.
Kristine holds a Ph.D. in Bioengineering from the University of California Los Angeles, which was supported in part by the prestigious National Science Foundation Graduate Research Fellowship, and a B.S. degree in Chemical Engineering from Ohio University.
Mark is the Executive Director of Corporate and Business Innovation for the Riverside Community College District. He is the former Executive Director of TriTech SBDC, an SBA organization that worked with high technology high growth firms by offering no cost consulting and training to entrepreneurs and businesses looking for go-to-market strategies that will accelerate the growth of their enterprise. Mark led TriTech SBDC to be the fifth highest producing SBDC in terms of Economic Impact in the nation and the highest performing organization out of 950 SBDCs in ROI.
As a public speaker, Mark has delivered programs on leadership, sales, marketing, customer service and team building that resulted in a workforce that was inspired with new tools to unleash their personal power to achieve higher levels of excellence. He has received the U.S. Small Business Administration Small Business Development Center Service Excellence and Innovation Center Award and the California Small Business Development Center Service Excellence & Innovation Award.
Dwayne is an attorney with a background in technology and intellectual property law. After a decade developing and protecting intellectual property at IBM, Dwayne moved to Southern California in 2013 to pursue a project of his own design. Today he remains active in the local start-up community by contributing as an expert-in-residence at schools and technology incubators.
Dwayne completed B.S. and M.S. degrees in Computer Science at Oakwood College and the University of Central Florida, his J.D. at Georgetown University Law Center. Dwayne is licensed to practice law in New York, New Jersey, the District of Columbia and in patent cases before the United States Patent and Trademark Office. Dwayne is a member of the National Association of Patent Practitioners.
Business Development, Sales and Marketing, Clinical Trials
Laura is a decisive leader with 25+ years of experience in the healthcare industry, with particular expertise in business development, sales/marketing strategy and clinical trials. She has demonstrated success in generating multimillion-dollar revenue by implementing innovative technology approaches in clinical trials market, establishing relationships with numerous pharmaceutical, biotechnology and medical device companies.
Laura is uniquely positioned to transition to the evolving healthcare information technology industry based on deep understanding of the healthcare market and integration of electronic medical records standards and software-based patient care solutions. She has a track record of utilizing strong analytical skills to evaluate marketplace and design strategy to secure new business, as shown by winning 6 Clinical Research Organization service contracts with cumulative value of $8.2M+.
Exceptional communicator with highly refined skills in negotiation and cultivating ongoing relationships, and significant global business experience through travel to 31 countries; speaks conversational French, beginning Mandarin.
For more than two decades, Arie managed and led software projects, software creation and implementations and ran operations with sales responsibility for publicly traded software vendors.
Subsequently, he has enjoyed a diverse and successful consulting career growing companies and leveraging business opportunities. With his broad international background, experience and training, he has successfully guided a wide range of companies, including B2B, B2C and non-profit organizations. In addition to technology project management, Arie is expert in creating and implementing management strategy: developing and executing market penetration, defining strategies for growth and allocating resources to achieve them, and selecting and negotiating joint venture opportunities.
Software creation and implementation, Executive Sales and Business Development, Branding and Marketing, Technology Project Management, Entrepreneur and Investor.
Jillian is one of the country’s leading experts on securities Regulation A+. Since 2008, Jillian has submitted multiple Regulation A Offering Circulars to the Securities Exchange Commission for approval making her one of the few attorneys familiar with the law prior to the changes under the JOBS Act.
Since the JOBS Act, Jillian has assisted multiple companies and entrepreneurs realize their fundraising goals through Crowdfunding, 506©, and Regulation A. Jillian also continues to specialize in transactional legal matters such as private placement memorandums, S-1’s/S-11’s, and Regulation D filings.
Jillian also spends her time speaking at seminars educating real estate investors on how to legally raise capital for their real estate investment projects. Jillian is the author of the highly rated book, The Crowdfunding Myth which debunks the multiple myths surrounding crowdfunding and teaches the reader how to effectively crowdfund their securities offering.
John is Chief Scientific Officer at CareDx, Inc., a California based molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients.
Dr. Sninsky is a member of American Association for the Advancement of Science, Association of Molecular Pathologists, American Society Human Genetics, American College Medical Genetics, American Association Cancer Research and American Association for the Study of Liver Disease. He is the author of more than 100 scientific papers including methods in molecular biology, application of the polymerase chain reaction (PCR) to virology and cancer, and genome-wide genetic association studies for multiple common, complex diseases.
Among John’s past awards are the Centers for Disease Control Charles C. Shepherd Science Award (1988), the Pan American Society for Clinical Virology Award (1992) and the Hoffmann-La Roche R & D Prize in 1997 for his efforts in applying PCR to virology and developing assays for measuring viral load in individuals with HIV. Dr. Sninsky was a recipient of the Purdue University Distinguished Alumni Award in 2001.
John brings experience in the discovery, development and application of diagnostic technologies, content and interpretive test solutions ranging from early stage biotechnology to international pharmaceutical organizations as well as in a range of small and enterprise diagnostic services and product settings.
Dr. Spinosa served as Medical Director or Associate Medical Director for several specialty clinical laboratories in California, as Partner of Laboratory Diagnostics Medical Group, served as the Chief of Staff-Elect at Scripps Memorial Hospital in La Jolla and has served as Laboratory Director of Verinata Health, Inc. since 2010.
He has over 10 years experience chairing pathology departments and served as Medical Director at Scripps East County from 1997 to 2000. Dr. Spinosa has been an Active Leader within the hospitals he covers.
He serves as Member of Executive Advisory Board at Sunquest Information Systems, Inc. He served as a Member of the Medical Advisory Board of Aperio Technologies, Inc. since September 2007. Dr. Spinosa is a Practicing Pathologist and has been a Member of the medical staffs at Scripps Memorial Hospital La Jolla and Scripps Memorial Hospital Encinitas.
From 1994 to 2003, Dr. Spinosa served on the CAP Informatics Committee, was the CAP voting representative at HL7, and represented the CAP on the ANSI Health Information Standards Board. Dr. Spinosa has been a Member of CAP since 1992. He is certified by the National Board of Medical Examiners and by the American Board of Pathology in anatomic and clinical pathology. He has Bachelor’s Degree from Claremont McKenna College and an M.D. and Ph.D. from the University of California San Diego. He completed a fellowship in hematopathology.
We have established a number of partnerships with like-minded organizations from around the world. Here is a list of some of the organizations that we are working with:
It is estimated that one in seventeen people are born with or develop a rare disease during their lifetime. At least 80% of rare diseases have an identified genetic component, with 50% of new cases of rare diseases being identified in children. However, it can take considerable time and expense between a patient first presenting at a doctors and receiving an accurate diagnosis. The time taken to sequence a whole human genome has been dramatically reduced and will become more affordable for routine use as the price continues to fall.
Genomics England is a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to sequence 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. Genomics is made up of many moving parts − from the understanding and consent of the public, to truly pioneering research, to building an effective NHS infrastructure. The Discovery Forum and the industry partnerships it builds are every bit as important to the success of genomic medicine.
The Global Alliance for Genomics and Health (GA4GH) is an international, nonprofit alliance formed in 2013 to accelerate the potential of research and medicine to advance human health. Bringing together 500+ leading organizations working in healthcare, research, patient advocacy, life science, and information technology, the GA4GH community is working together to create frameworks and standards to enable the responsible, voluntary, and secure sharing of genomic and health-related data. All of our work builds upon the Framework for Responsible Sharing of Genomic and Health-Related Data.
GA4GH Connect is a five-year strategic plan that aims to drive uptake of standards and frameworks for genomic data sharing within the research and healthcare communities in order to enable responsible sharing of clinical-grade genomic data by 2022. GA4GH Connect links our Work Streams with Driver Projects—real-world genomic data initiatives that help guide our development efforts and pilot our tools.
Southern California Biomedical Council (SoCalBio) is a nonprofit, member-supported trade association that serves the biotech, med tech, IVD and digital health communities in the six counties that comprise the Greater Los Angeles region (Los Angeles, Orange, Ventura, Santa Barbara, Riverside and San Bernardino). SoCalBio’s programs help local firms gain access to capital, potential partners, and other business services. The Council also promotes technology transfer and workforce training, while informing policymakers and the public at-large about the benefits of the region’s bioscience industry. SoCalBio is open to membership by firms and organizations engaged in all aspects of bioscience research, technology development, and commercialization. All of the incubator companies at Murrieta Genomics receive a complimentary membership to SoCalBio.
Hello Tomorrow is a non-profit organisation bringing together a community of actors aiming to unlock the potential of deep technologies to solve the world’s toughest challenges. We source deeptech projects and startups and facilitate collaboration between entrepreneurs, industries and investors in order to propel innovation from the lab to the market.
Hello Tomorrow organizes startup competitions, mentorship programs and a series of events around the world, as well as educating and consulting relevant stakeholders on emergence of deep technologies. Hello Tomorrow is fast becoming a key reference platform in deeptech innovation and entrepreneurship.